3种依达拉奉联合用药方案治疗急性脑梗死的最小成本分析
x

请在关注微信后,向客服人员索取文件

篇名: 3种依达拉奉联合用药方案治疗急性脑梗死的最小成本分析
TITLE:
摘要: 目的:探讨银杏达莫、阿加曲班和奥扎格雷钠分别联合依达拉奉治疗急性脑梗死的药物经济学效果。方法:运用回顾性调查法,将64例急性脑梗死住院患者按不同用药方案分为A组(银杏达莫+依达拉奉)22例、B组(阿加曲班+依达拉奉)19例、C组(奥扎格雷钠+依达拉奉)23例,治疗7~14 d后观察各组方案的疗效;并计算治疗成本,采用最小成本分析法进行药物经济学评价。结果:3组方案的总有效率比较,差异无统计学意义(P>0.05);A、B、C组方案治疗急性脑梗死的成本分别为8 746.36、10 770.64、    8 264.67元;敏感度分析结果与最小成本分析结果一致。结论:奥扎格雷钠+依达拉奉的方案治疗急性脑梗死较为经济。
ABSTRACT: OBJECTIVE: To explore the pharmacoeconomic effect of Ginkgo dipyidamolum, argatroban or sodium ozagerl combined with edaravone in the treatment of acute cerebral infarction (ACI). METHODS: In retrospective study, 64 ACI patients were divided into group A (Ginkgo dipyidamolum+edaravone, 22 cases), group B (argatroban+edaravone, 19 cases) and group C (sodium ozagerl+edaravone, 23 cases). Therapeutic efficacies were observed after 7-14 days of treatment; therapy cost was calculated, and cost-minimization analysis was used to evaluate pharmacoeconomics. RESULTS: There was no statistical significance in total effective rate among 3 groups (P>0.05); the costs of group A,group B and group C were 8 746.36 yuan,10 770.64 yuan and 8 264.67 yuan. Results of sensitivity analysis were in line with those of cost-minimization analysis. CONCLUSIONS: Therapy plan of sodium ozagerl+edaravone is the economical regime in the treatment of ACI.
期刊: 2016年第27卷第5期
作者: 乔 媛,储秋萍
AUTHORS: QIAO Yuan,CHU Qiuping
关键字: 急性脑梗死;依达拉奉;银杏达莫;阿加曲班;奥扎格雷钠;联合用药;最小成本分析法
KEYWORDS: Acute cerebral infarction; Edaravone; Ginkgo dipyidamolum; Argatroban; Sodium ozagerl; Drug combination; Cost-minimization analysis
阅读数: 322 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!